Actively Recruiting
Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)
Led by American University of Beirut Medical Center · Updated on 2023-02-03
700
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
A
American University of Beirut Medical Center
Lead Sponsor
P
PneumoADIP
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying invasive pneumococcal disease caused by the bacterium Streptococcus pneumoniae, which can lead to serious infections like meningitis, pneumonia, and bloodstream infections in both children and adults. The study aims to identify the different serotypes of this bacterium causing disease in Lebanon and to understand their sensitivity to various antibiotics. This information will help assess the usefulness of current pneumococcal vaccines in preventing these infections and will be shared with healthcare providers and the Ministry of Health in Lebanon. This observational study collects bacterial samples from blood, cerebrospinal fluid, and other sterile body fluids from patients of all ages admitted to hospitals across Lebanon with invasive pneumococcal infections. These samples are analyzed to determine the types of pneumococcal bacteria present and their antibiotic resistance patterns. The study does not involve administering treatments or interventions but focuses on gathering important data over time. Participants contribute by providing bacterial isolates from confirmed infections during their hospital stay. Researchers will monitor the prevalence of pneumococcal serotypes yearly and study their antibiotic sensitivity. The study involves reviewing these samples and sharing findings with medical professionals to improve prevention strategies. This long-term program started in 2005 and will continue through 2030, with ongoing collection and analysis of samples to better understand pneumococcal disease in Lebanon.
CONDITIONS
Brief Title
Lebanese Interhospital Pneumococcal Surveillance Program
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Samples must be culture proven invasive pneumococcal infections
- Patients of all ages admitted to hospitals throughout Lebanon
- Acceptable samples include positive isolates from blood, cerebrospinal fluid, empyema fluid, abscesses, joint fluid, middle ear fluid from surgery, and lung needle aspiration
You will not qualify if you...
- Samples that are not Streptococcus pneumoniae isolates
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Ongoing until October 2030
Participants provide samples from culture proven invasive pneumococcal infections for analysis.
Samples collected as part of hospital admission
Duration - Yearly until October 2030
Participants' samples are monitored yearly to determine serotype prevalence and antibiotic sensitivity of S. pneumoniae.
Annual assessments based on collected samples
Trial Site Locations
Total: 1 location
1
American University of Beirut
Beirut, Lebanon, 113-6044
Actively Recruiting
Research Team
G
Ghassan S Dbaibo, M.D.
M
Mireille Lteif, RN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here